In recent years, multiple probiotics have been tested in randomized controlled trials for IBS (Irritable Bowel Syndrome), but due to differences in strain tested and methodology, making recommendations concerning which probiotics are beneficial for the management of IBS has been difficult to date.
A new well-conducted meta-analysis by renowned gastroenterology experts has been published in the most prominent journal for the field: Gastroenterology, the official journal of the American Gastroenterological Association.
In this study, the authors assessed three endpoints in IBS populations: global symptoms—abdominal pain—bloating, or distension.
Discover the key facts on the study and how S. cerevisiae CNCM I-3856 is now acknowledged as one of the most documented probiotic strains for IBS symptom management, specifically for abdominal pain.
Latest news & videos<span data-metadata="">
- Adonat®
- MenaQ7®
- Mythocondro®
- Oct 01, 2024
Gnosis by Lesaffre Showcases at Denk Ingredient’s Annual Symposium in Munich
Gnosis by Lesaffre was a key presenter for Denk Ingredients' annual symposium in Munich,...
- Corporate
- News
- Sep 30, 2024
Successful Vitafoods Asia:
Gnosis Showcases Innovative Nutraceutical Solutions
Gnosis by Lesaffre had an exciting and fruitful participation at Vitafoods Asia last week,...
- Adonat®
- Download
- Mobility & Joint
- Sep 24, 2024
Adonat® Premium SAMe:
Your Comprehensive Solution for Up-and-Coming Health Challenges
Explore exclusive opportunities for the brand in the world market, symbolizing the know-how, competence,...
